Navigation Links
Halozyme Therapeutics Reports Third Quarter 2011 Financial Results
Date:11/7/2011

million, compared with $12.4 million for the third quarter of 2010, primarily due to an increase in manufacturing activities and clinical trial activities.  
  • Selling, general and administrative expenses for the third quarter of 2011 were $4.3 million, compared to $3.4 million for the third quarter of 2010. The increase for SG&A results from higher marketing expenses and legal expenses during the quarter.  
  • Cash and cash equivalents were $66.3 million as of September 30, 2011, compared with $83.3 million as of December 31, 2010 and $89.8 million as of September 30, 2010. Net cash used in the third quarter of 2011 was approximately $12.8 million.
  • For 2011, the Company expects operating expense  to be at the low end of the 15% - 20% operating expense growth guidance previously given. The Company expects net cash burn to be at the low end of the previously guided range of $30 and $35 million.

  • Conference CallHalozyme management will host a conference call and webcast on November 7, 2011 to discuss these topics beginning at 4:30 p.m. EST (1:30 p.m. PST). To participate via telephone, please call 877.407.8037 for domestic callers or 201.689.8037 for international callers. A telephone replay will be available beginning shortly after the end of the call by dialing 877.660.6853 from the U.S. or 201.612.7415 for international callers and using account # 367 and replay ID # 376771. The conference call will be broadcast live over the Internet at www.halozyme.com and the replay will be available on the company's Web site for seven days.

    About Halozyme TherapeuticsHalozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets. The Company's product portfolio is based primarily on intellectual property covering the family of human enzymes kno
    '/>"/>

    SOURCE Halozyme Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Halozyme Therapeutics Announces Data From Two Phase 1 Studies of PEGPH20 Demonstrating Targeting of Hyaluronan in Tumor Stroma
    2. Halozyme Begins Clinical Trial with HTI-501 in Women with Edematous Fibrosclerotic Panniculopathy
    3. Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
    4. Halozyme Therapeutics to Present Data on its Ultrafast Insulin Programs at the Upcoming American Diabetes Association 71st Scientific Sessions
    5. Halozyme Therapeutics to Present at the Jefferies 2011 Global Healthcare Conference on June 9
    6. Halozyme Therapeutics Reports First Quarter 2011 Financial Results
    7. Halozymes Ultrafast Insulin Generates Faster-In and Faster-Out Profile for Type 1 Diabetes Patients Using Insulin Pumps
    8. Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab)
    9. Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
    10. Halozyme Receives $5.5 Million Payment From Baxter
    11. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/1/2015)... , June 1, 2015 ... announced the addition of the "Global PDT ... offering.        (Logo: ... Report 2014 is a professional and in-depth study ... , ,The report provides a basic overview of ...
    (Date:6/1/2015)... , June 1, 2015  Fennec Pharmaceuticals, ... of positive interim results from a poster presented ... open label randomised phase III trial of the ... in patients receiving cisplatin (Cis) monotherapy for standard ... the American Society of Clinical Oncology (ASCO) 2015 ...
    (Date:6/1/2015)... Sistemic Ltd. and RoosterBio Inc. ... commercial collaboration agreement and signed a memorandum of ... and work together towards advancing the field of ... Sistemic will collaborate on utilizing microRNA (miRNA)-based cell ... and relevant characterization panels for hMSC products and ...
    (Date:6/1/2015)... -- Berg, a biopharmaceutical company committed to uncovering health solutions ... its trials using its cancer drug BPM 31510 on ... negative breast cancer, at the 51 st Annual ... May 29 – June 2 in Chicago ... of the first cancer drugs guided in development by ...
    Breaking Biology Technology:Global PDT Machine Industry Report 2014 2Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 2Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 3Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 4Sistemic and RoosterBio Inc Announce Broad Collaboration Agreement to Advance miRNA and Mesenchymal Stem/Stromal Cell (MSC) Regenerative Technology 2Sistemic and RoosterBio Inc Announce Broad Collaboration Agreement to Advance miRNA and Mesenchymal Stem/Stromal Cell (MSC) Regenerative Technology 3Sistemic and RoosterBio Inc Announce Broad Collaboration Agreement to Advance miRNA and Mesenchymal Stem/Stromal Cell (MSC) Regenerative Technology 4Berg Presents Data On BPM 31510 Solid Tumor Trial At ASCO Annual Meeting That Reveals The Promise Of Metabolically Driven Therapy 2Berg Presents Data On BPM 31510 Solid Tumor Trial At ASCO Annual Meeting That Reveals The Promise Of Metabolically Driven Therapy 3
    ... , Introduction , ... almost all color , vision and most of the ... known as the macula , lutea, or yellow spot, ... and zeaxanthin. , These compounds are both, ...
    ... Polyphosphoinositides and their metabolites are, ... responses to a number of hormones and growth, ... that phosphorylates PI at the 3 position of, ... metabolism and potential intracellular signals., ...
    ... , Agencourt offers sequencing services designed specifically for ... cDNA sequencing and finishing. Agencourt , has many features ... with rapid project turnaround including: Comprehensive genomic , ... High throughput, GLP-compliant facility , ...
    Cached Biology Technology:Purification of the Components of Human Macular Carotenoid-Binding Complex, , Rev A 2Purification of the Components of Human Macular Carotenoid-Binding Complex, , Rev A 3Purification of Phosphoinositide 3-Kinase With UNO Columns 2cDNA Sequencing & Finishing 2
    (Date:4/20/2015)... 20, 2015 The announcement comes ... Glenbeigh Records Management (GRM), Ireland,s foremost ... Bank. Having built up an impressive track record of clients ... player within the records management sector in Dubai ... is GCC staffbase and employ a further eight staff members ...
    (Date:4/14/2015)... NEW YORK , April 14, 2015 /PRNewswire/ ... Fast IDentity Online (FIDO ® ) Alliance tm ... standards-based specifications. FIDO members commit to share technology ... authentication methods that are interoperable, more secure and ... specifications enable biometric identity verification that protects sensitive ...
    (Date:4/13/2015)... 13, 2015 According to ... Biometrics Market Forecast & Opportunities, 2020", the global biometrics ... around 14% till 2020. The biometrics market is ... implementation and review of biometric management systems. The ... products with greater efficiency, are resulting in increasing ...
    Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2
    ... considered sexy, but it may prove a permanent turn on for ... BMC Genomics could help explain why former smokers are still more ... A Canadian team led by Wan L Lam and Stephen ... of 24 current and former smokers, as well as from non-smokers ...
    ... Government priorities can drive local waste partnerships towards the ... wider sustainable waste management objectives, a study funded by ... levels of waste and disposing of it in environmentally ... in other areas of public service delivery, partnership working ...
    ... may soon be cleaner thanks to an innovative approach ... and funded by the U.S. Environmental Protection Agency (EPA). ... and planners select the most efficient and site specific ... controlling the amount of pollutants that enter the receiving ...
    Cached Biology News:Smoking turns on genes -- permanently 2Central targets may hinder wider waste management objectives 2Central targets may hinder wider waste management objectives 3Innovative civil engineering application promises cleaner waters 2Innovative civil engineering application promises cleaner waters 3
    NovaScreen offers cell biology, cell culture and molecular biology services for companies who lack a cell culture facility....
    Standard and modified oligonucleotides up to 150 nt-long at any scale for broad applications. Price starts from 30p/base (10 nmole scale)....
    ... identification through targeting resequencing. This ... assay validation/optimization, high throughput PCR setup ... samples and sequence alignment and analysis.,Agencourts ... and highly accurate identification of SNP ...
    ... JMP 6 delivers enhanced statistics and ... and quality improvement managers. As an ... JMP 6 simplifies statistics for novice ... needed by experts. It offers a ...
    Biology Products: